Our Team
Edward R. Sauter, MD, PhD,
Associate Professor of Surgery directs the Breast Cancer Prevention and Early
Detection Laboratory with the goal of identifying markers, or indicators, of breast
cancer risk. Dr. Sauter received his medical degree from Louisiana State
University in New Orleans and his doctor of philosophy degree from the University
of Pennsylvania. His surgical residency was conducted at the Ochsner Clinic and
Hospital in New Orleans, and his fellowship in surgical oncology at Fox Chase
Cancer Center in Philadelphia.
Dr. Weizhu Zhu has over 10 years of molecular biology
experience. Most recently he has focused on DNA and RNA analyses of non- and minimally
invasive techniques to screen for breast cancer, as well as evaluate response to therapy.
Dr. Wenyi Qin is an expert in real-time PCR and
quantitative PCR. She is using molecular becon technology to image breast lesions
before they develop into invasive malignancies.
Dr. Zhong Guohua is a trained pathologist who is
currently performing PCR, RT-PCR, and Western blotting of breast epithelial cells
and tissue.
Lisa Schlatter, RN, enrolls patients on our
clinical trials, performs database entry, interviews prospective candidates, and
collects nipple aspirate fluid samples.
Jenny Haubner, RN, enrolls patients on our
clinical trials, performs database entry, interviews prospective candidates, and
collects nipple aspirate fluid samples.
Leslie Harvey, RN, enrolls patients on our
clinical trials, performs database entry, interviews prospective candidates, and
collects nipple aspirate fluid samples.
Karen Geren is the grants coordinator for
the Breast Cancer Prevention and Early Detection Laboratory and for the
Department of Surgery.
Joseph Magee, MD, is with the
Department of Surgery.
Research Collaborators
In the Alexander Lab at
the University of Missouri-Columbia,
research is being done into mechanisms of resistance to anticancer drugs and DNA repair.
Chemotherapy is widely used to treat many different types of cancer. However, a widespread
problem is that tumors can become resistant to the drugs used for the treatment. Little is
known about the molecular mechanisms underlying drug resistance. Over the past few years
Hannah and Steve Alexander have been investigating how cells respond to, and repair, DNA
damage caused by UV light and chemicals including the widely used anticancer drug cisplatin.
|
Stefanie S. Jeffrey, MD
John and Marva Warnock Faculty Scholar in Cancer Research
Associate Professor and
Chief of Breast Surgery
Stanford University School of Medicine
Dr. Jeffrey's specialty is genomic analysis of the
breast using microarray technology. Microarrays are
used to analyze the genetic material within breast cancer to determine which genes
in the tumor are active or inactive on a genome-wide scale.
The Jeffrey Lab
focuses on breast cancer research and is part of a collaborative group involved
in a major effort to define molecular subtypes of breast cancer.
|
|
Eleftherios P. Diamandis, MD, PhD
Professor and Head, Division of Clinical Biochemistry,
Department of Laboratory Medicine and Pathobiology,
Faculty of Medicine, University of Toronto,
Banting Institute; and
Head, Clinical Biochemistry Section,
Pathology and Laboratory Medicine Department,
Mount Sinai Hospital
Toronto, Ontario, Canada
The Toronto Kallikrein Laboratory, directed by Dr. Eleftherios Diamandis, is an international leader in the study of
the human kallikrein gene family. Their investigations span from very basic (gene
discovery, transcriptional regulation, discovery of novel protein function) to
applied clinical research, involving patients (translational research). They seek
better ways of diagnosis, prognosis, and monitoring of human disease. Regarding
human disease, their major focus is on cancer, especially endocrine-related
cancers, including ovarian, breast, and prostate cancer.
|
|
Garrett C. Du Bois, PhD
Associate Professor of Microbiology and Immunology
Kimmel Cancer Center, Thomas Jefferson University,
Philadelphia, PA
The Du Bois Laboratory
employs protein chemical and mass spectrometric methods to understand the
structure and function of proteins encoded by the Tcl1 oncogene family as well
as the accessory proteins, nef, vif, and vpu of the human immunodeficiency
virus (HIV). Our current research also focuses on breast cancer research in two
areas. One study in collaboration with Drs. Eva Surmacz and Edward Sauter
involves the role of epithelins and proepithelin in breast cancer progression.
The other project, in collaboration with Dr. Sauter, uses SELDI (Surface Enhanced
Laser Desorption/Ionization) mass spectrometry to rapidly profile differential
protein expression in nipple aspirate fluid (NAF) and ductoscopic samples from
women with non-diseased mammary glands (normal) and from women with breast tumors
to develop a rapid, minimally-invasive method for assessment of breast cancer risk.
Additionally, Dr. Du Bois serves as director of the
Protein/Peptide Chemistry and Molecular
Interaction Facility of Kimmel Cancer Center.
|
Top
|
|
|
